References

  1. Nexplanon 68 mg implant for subdermal use – Summary of Product Characteristics, October 2008. View [Accessed August 2009]
  2. National Institute for Health and Clinical Excellence. Long-acting reversible contraception. Quick reference guide. NICE Clinical Guideline 30. London: National Institute for Health and Clinical Excellence, 2005. View [Accessed August 2009]
  3. National Institute for Health and Clinical Excellence. NICE Clinical Guidelines CG30. Long Acting Reversible Contraception: The Effective And Appropriate Use Of Long-Acting Reversible Contraception. London: NICE, 2005. View [Accessed August 2009]
  4. Hohmann H, Creinin M. The contraceptive implant. Clin Obstet Gynecol 2007; 50(4): 907–917.
  5. Levine JP, Sinofsky FE, Christ MF; Nexplanon US Study Group. Assessment of Nexplanon insertion and removal. Contraception 2008; 78(5): 409–417.
  6. Graesslin O, Korver T. The contraceptive efficacy of Nexplanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008; 13(Suppl. 1): 4–12.
  7. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. Cochrane Database Syst Rev 2007; 3: CD001326.
  8. Funk S, Miller M, Mishell D, et al. Safety and efficacy of Nexplanon™, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005; 71(5): 319–326.
  9. Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot study on the efficacy and safety of Nexplanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3(2): 85–91.
  10. Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Nexplanon compared with Norplant. Fertil Steril 1998; 69(4): 714–721.
  11. Smith A, Reuter S. An assessment of the use of Nexplanon in three community services. J Fam Plann Reprod Health Care 2002; 28(4): 193–196.
  12. Agrawal A, Robinson C. An assessment of the first 3 years' use of Nexplanon in Luton. J Fam Plann Reprod Health Care 2005; 31(4): 310–312.
  13. Otero Flores JB, Balderas ML, Bonilla MC, Vázquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet 2005; 90(3): 228–33.
  14. Lipetz C, Phillips CJ, Fleming CF. The cost-effectiveness of a long-acting reversible contraceptive (Nexplanon) relative to oral contraception in a community setting. Contraception 2009; 79(4): 304–309.
  15. Faculty of Family Planning and Reproductive Health Care (FFPRHC). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2005/2006. London: FFPRHC, 2006.
  16. Faculty of Sexual and Reproductive Healthcare (FSRH). Clinical Guidance. Progestogen-only Injectable Contraception. London: FSRH, 2009.
  17. Riney S, O'Shea B, Forde A. Etonogestrel implant as a contraceptive choice; patient acceptability and adverse effect profile in a general practice setting. Ir Med J 2009; 102(1): 24–25.
  18. Gezginc K, Balci O, Karatayli R, Colakoglu MC. Contraceptive efficacy and side effects of Nexplanon®. Eur J Contracept Reprod Health Care 2007; 12(4): 362–365.
  19. Rai K, Gupta S, Cotter S. Experience with Nexplanon® in a north-east London family planning clinic. Eur J Contracept Reprod Health Care 2004; 9(1): 39–46.
  20. Davie JE, Walling MR, Mansour DJ, Bromham D, Kishen M, Fowler P. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996; 18(1):150–159. 
  21. den Tonkelaar D, Oddens BJ. Factors influencing women's satisfaction with birth control methods. Eur J Contracept Reprod Health Care 2001; 6(3):153–158.
  22. Lakha F, Glasier AF. Continuation rates of Nexplanon® in the UK: data from an observational study in a clinical setting. Contraception 2006; 74(4): 287–289.
  23. Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception 2002; 65(1): 29–37.
  24. Benagiano G, Bastianelli C, Farris M. Hormonal contraception: state of the art and future perspectives. Minerva Ginecol 2007; 59(3): 241–270.
  25. Erkkola R. Recent advances in hormonal contraception. Curr Opin Obstet Gynaecol 2007; 19(6): 547–553.
  26. Simon M, Shulman LP. Alternatives to oral regimens of contraception. Minerva Ginecol 2007; 59(3): 271–286.
  27. Peterson HB, Curtis KM. Long-acting methods of contraception. N Engl J Med 2005; 353: 2169–2175.
  28. Kane R, Irving G, Brown S, Parkes N, Walling M, Killick S. Long-acting, reversible and permanent methods of contraception: insight into women's choice of method. Qual Prim Care 2009; 17(2): 107–114.
  29. Spencer AL, Bonnema R, McNamara MC. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. Am J Med 2009; 122(6): 497–506.
  30. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Nexplanon®. Contraception 1998; 58(6 Suppl. 1): 91–97.
  31. Davies GC, Feng LX, Newton JR, Van Beek A, Coelingh-Bennink HJ. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993; 47(3): 251–261.
  32. Weisberg E, Fraser I. Australian women's experience with Nexplanon. Aust Fam Physician 2005; 34(8): 694–696.
  33. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 1986; 34(3):253–260.
  34. Reuter S, Smith A. Nexplanon®: user views in the first year across three family planning services in the Trent Region, UK. Eur J Contracept Reprod Health Care 2003; 8(1): 27–36.
  35. Beerthuizen R, van Beek A, Massai R, Mäkäräinen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Nexplanon® compared to a non-hormonal method of contraception. Hum Reprod 2000; 15(1): 118–122.
  36. World Health Organization Department of Reproductive Health and Research (WHO/RHR). Medical Eligibility Criteria for Contraceptive Use. Geneva: WHO, 2004.
  37. World Health Organization Department of Reproductive Health and Research (WHO/RHR). Medical Eligibility Criteria for Contraceptive Use. 2008 update. Geneva: WHO, 2008.
     

 


Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.gov.uk.
Adverse events should also be reported to MSD Drug Safety Department on 01707 363773

Organon

Terms and Conditions
Privacy Policy

Date of Preparation 6/2011
Code 6/12 - NEX.10.GB.9260.AVc

© 2010 Copyright Organon Laboratories Limited. All rights reserved.